Table 6.

Costs distribution according to scenario 1 to 4 from the societal perspective

	Unitary cost (US$)	Amount	Total (US$)
Scenario 1
Hexavalent (DTaP-IPV-HepB-Hib) vaccine	19.80	997,877	19,757,965
Pentavalent (DTwP-Hib-HepB) vaccine	2.85	966,933	2,754,539
Average IPV (1) + bOPV (3) = 3.6 + (0.32*3) = 4.5	1.14	966,933	1,102,304
Difference of schemes	15.81	966,933	15,288,431
Additional costs of the simultaneous scheme			8,838,805
Cost to society			6,449,627
Scenario 2
Hexavalent (DTaP-IPV-HepB-Hib) vaccine	19.80	997,877	19,757,965
Pentavalent (DTwP-Hib-HepB) vaccine	2.85	966,933	2,754,539
IPV four doses- average = 3.60	3.6	966,933	3,480,959
Difference of schemes	13.35	966,933	12,909,776
Additional costs of the simultaneous scheme			8,838,805
Cost to society			4,070,971
Scenario 3
Hexavalent (DTaP-IPV-HepB-Hib) vaccine	19.80	997,877	19,757,965
Pentavalent (DTwP-Hib-HepB) vaccine	2.85	966,933	2,754,539
IPV four-dose bottle plus syringe = 2.10	2.10	966,933	2,030,559
Difference of schemes	14.85	966,933	14,360,176
Additional costs of the simultaneous scheme			8,838,805
Cost to society			5,521,371
Scenario 4
Hexavalent (DTaP-IPV-HepB-Hib) vaccine	19.80	997,877	19,757,965
Pentavalent (DTwP-Hib-HepB) vaccine	2.85	966,933	2,754,539
IPV four doses- pre-filled syringe = 5.10	5.10	966,933	4,931,358
Difference of schemes	11.85	997,877	11,459,377
Additional costs of the simultaneous scheme			8,838,805
Cost to society			2,620,572

bOPV bivalent oral polio vaccine, IPV inactivated polio vaccine